PNP

Purine nucleoside phosphorylase

29,088 patent compounds predicted against PNP, 17,075 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ulodesine (SCHEMBL474735)	1.00	18/20
SCHEMBL18249	1.00	17/20
SCHEMBL505891	0.65	16/20
SCHEMBL505433	0.62	16/20
SCHEMBL506019	0.60	14/20
SCHEMBL505834	0.55	14/20
SCHEMBL505570	0.65	13/20
SCHEMBL505960	0.54	12/20
SCHEMBL489056	0.70	11/20
Hydrochloric Acid (SCHEMBL258897)	0.69	11/20
Trifluoroacetic Acid (SCHEMBL631061)	0.59	11/20
Acyclovir (SCHEMBL3175)	1.00	10/20
SCHEMBL18248	1.00	10/20
Acyclovir (SCHEMBL40724)	0.97	10/20
Forodesine (SCHEMBL506383)	0.75	10/20
SCHEMBL571645	0.72	10/20
SCHEMBL505709	0.64	10/20
SCHEMBL505326	0.56	10/20
SCHEMBL146427	0.50	10/20
SCHEMBL554861	0.42	10/20

Germline variants in PNP on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PNP gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PNP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla	PHASE4	COMPLETED
Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults	PHASE4	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects	PHASE3	COMPLETED
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	PHASE3	UNKNOWN
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis	PHASE3	COMPLETED
A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine	PHASE3	COMPLETED
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer	PHASE1/PHASE2	COMPLETED
Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity	PHASE2	COMPLETED
A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa	PHASE1/PHASE2	COMPLETED
A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa	PHASE1/PHASE2	COMPLETED
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV	PHASE1/PHASE2	COMPLETED
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients	PHASE2	COMPLETED
Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men	PHASE2	COMPLETED
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
BAY43-9006 - Phase II in Advanced Breast Cancer	PHASE2	COMPLETED
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial	PHASE2	COMPLETED
Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma	PHASE2	UNKNOWN
Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir	PHASE2	COMPLETED
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence	PHASE2	COMPLETED
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion	PHASE1	COMPLETED
Irinotecan and Capecitabine in Treating Patients With Solid Tumors	PHASE1	COMPLETED
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis	nan	UNKNOWN
Investigation of ADA Enzyme Deficiency	nan	UNKNOWN
A RETROspective Study of Patients With TK2d	nan	COMPLETED
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E	nan	UNKNOWN
Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)	nan	COMPLETED
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.	nan	COMPLETED
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PNP binder may also engage these)

Protein	Name	Similarity
P85973	—	1.000	P85973 →
P23492	—	1.000	P23492 →
P55859	—	1.000	P55859 →
P77834	—	0.993	P77834 →
P45563	—	0.990	P45563 →
P46354	—	0.988	P46354 →
P0DJF9	—	0.983	P0DJF9 →
Q05788	—	0.979	Q05788 →
Q87BR7	—	0.978	Q87BR7 →
C1F1E7	—	0.978	C1F1E7 →
Q8YMD9	—	0.978	Q8YMD9 →
Q87ZC3	—	0.978	Q87ZC3 →
A8NEP3	—	0.978	A8NEP3 →
B0JU82	—	0.978	B0JU82 →
Q89VT5	—	0.977	Q89VT5 →
P0DJF8	—	0.977	P0DJF8 →
B0BU72	—	0.977	B0BU72 →
P13228	—	0.977	P13228 →
Q5KZ06	—	0.977	Q5KZ06 →
Q1DDB7	—	0.977	Q1DDB7 →
Q1GXH3	—	0.977	Q1GXH3 →
Q3AGF7	—	0.977	Q3AGF7 →
Q9KLL6	—	0.977	Q9KLL6 →
Q8D737	—	0.977	Q8D737 →
B3GX46	—	0.976	B3GX46 →
P77187	—	0.976	P77187 →
Q31JD2	—	0.976	Q31JD2 →
A0KVD1	—	0.976	A0KVD1 →
Q09816	—	0.976	Q09816 →
C0ZCG5	—	0.976	C0ZCG5 →